We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In response to questions from a Senate panel, Michael Leavitt, the nominee to become HHS secretary, said the FDA should soon have a new commissioner. Leavitt also vowed to guard the integrity of the FDA and other HHS agencies if confirmed.
Allowing for prescription drug imports, protecting government whistle-blowers and making the FDA more transparent will require strong leadership from the next HHS secretary, according to Senate Finance Committee Chairman Chuck Grassley (R-Iowa).
The FDA should have a new commissioner soon, said Michael Leavitt, the nominee to become HHS secretary, who also vowed to guard the integrity of the FDA and other HHS agencies if confirmed.
To help speed the availability of innovative medical products, HHS should create a forum that will enable investigators and developers to discuss their products with key research, regulatory and reimbursement agencies, according to an HHS task force report released Jan. 13.
Spending growth for prescription drugs in the U.S. decelerated at a rapid rate in 2003, according to new data released by the Centers for Medicare & Medicaid Services (CMS).
President Bush has nominated Environmental Protection Agency (EPA) Administrator Michael Leavitt to become the next secretary of HHS — a decision that surprised Washington observers who had expected former FDA Commissioner Mark McClellan to get the nod.
The primary methods of pricing drug products — through intellectual property rights and diversity pricing, which allows firms to charge higher prices to those with greater ability to pay — are under attack, says a free-market think tank in a new paper opposing drug importation proposals.
The increased use of generic drugs will provide more significant cost savings to consumers than practices such as drug importation and price controls, according to two government reports.
The importation of prescription drugs into the U.S. is possible, but any plan to do so must be limited to commercial shipments of high-volume, high-cost products from a country with drug safety precautions equivalent to those of the U.S., according to HHS' drug importation task force report, which added that any such system would produce only modest savings for consumers.